Southwestern Simmons Cancer Center
Southwestern Simmons Cancer Center
News Article | August 8, 2017
DALLAS - Aug. 8, 2017 - UT Southwestern Simmons Cancer Center researchers have shown that a first-in-class molecule can prevent breast cancer growth when traditional therapies stop working. First-in-class drugs are drugs that work by a unique mechanism, in this case a molecule that targets a protein on the estrogen receptor of tumor cells. The potential drug offers hope for patients whose breast cancer has become resistant to traditional therapies. "This is a fundamentally different, new class of agents for estrogen-receptor-positive breast cancer," said Dr. Ganesh Raj, Professor of Urology and Pharmacology at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center."Its unique mechanism of action overcomes the limitations of current therapies." All breast cancers are tested to determine if they require estrogen to grow and about 80 percent are found to be estrogen-sensitive. These cancers can often be effectively treated with hormone therapy, such as tamoxifen, but as many as a third of these cancers eventually become resistant. The new compound is a potential highly effective, next-line treatment for these patients, said Dr. Raj, part of UT Southwestern's Urologic Cancer Team. Traditional hormonal drugs, such as tamoxifen, work by attaching to a molecule called the estrogen receptor in cancer cells, preventing estrogen from binding to the receptor, a necessary step for cancer cells to multiply. But the estrogen receptor can mutate and change its shape over time so that the treatment drug no longer fits neatly with the receptor. When this happens, the cancer cells start multiplying again. "There has been intense interest in developing drugs that block the ability of the estrogen receptor - the prime target in most breast cancers - from interacting with the co-regulator proteins that cause a tumor's growth. Blocking such "protein-protein interactions" has been a dream of cancer researchers for decades. Dr. Raj and his colleagues have done the remarkable by discovering what could be the first in class of a therapeutic that realizes this dream," said Dr. David Mangelsdorf, Professor and Chairman of the Department of Pharmacology, who holds the Alfred G. Gilman Distinguished Chair in Pharmacology, and the Raymond and Ellen Willie Distinguished Chair in Molecular Neuropharmacology in Honor of Harold B. Crasilneck, Ph.D. The drug works by blocking other molecules &ndash proteins called co-factors - that also must attach to the estrogen receptor for cancer cells to multiply. The new molecule, dubbed ERX-11, mimics a peptide, or protein building block. So far, it has been tested in mice and in cancer cells removed from patients and works well in both models, and there have been no signs of toxicity in the tests. If successfully translated to a human therapy, another advantage of ERX-11 is that it could be taken orally by patients, rather than as an infusion. Dr. Raj said the group is hoping to get a clinical trial under way in about a year. The notion of blocking protein co-factors has implications for treatment of other cancers as well. "This could be a first-line breast cancer therapy down the line. It could even lead to new treatments for other hormone-sensitive cancers. For now, it offers hope for women with estrogen-sensitive breast cancer for whom conventional therapies fail," Dr. Raj said. The research appears in the online journal eLife. Other UT Southwestern researchers who participated in the study are Dr. Shihong Ma, senior research associate; Dr. Rui Li, senior research associate; Dr. Xihui Liu, Instructor in Urology; Shino Murakami, graduate student researcher; Dr. Wan-Ru Lee, research scientist; Dr. Vijay Gonugunta, research scientist; and Dr. Douglas Strand, Assistant Professor in Urology. Funding for the research was provided by the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, Department of Defense, Congressionally Directed Medical Research Programs, the Welch Foundation and the Mimi and John Cole Foundation. The Harold C. Simmons Comprehensive Cancer Center at UT Southwestern is the only NCI-designated Comprehensive Cancer Center in North Texas and one of just 48 NCI-designated Comprehensive Cancer Centers in the nation. The Harold C. Simmons Comprehensive Cancer Center is among only 30 U.S. cancer research centers to be designated by the National Cancer Institute as a National Clinical Trials Network Lead Academic Site.
Buzaglo J.S.,Research and Training Institute |
Miller S.M.,Fox Chase Cancer Center |
Kendall J.,Southwestern Simmons Cancer Center |
Stanton A.L.,University of California at Los Angeles |
And 5 more authors.
Journal of Cancer Survivorship | Year: 2013
Introduction: The NCI developed the print-based educational brochure, Facing Forward, to fill a gap in helping cancer patients meet the challenges of transitioning from active treatment to survivorship; however, little research has been conducted on its efficacy. Purpose: The aims of this study were to evaluate the efficacy of Facing Forward in promoting the uptake of recommended behaviors (e. g., ways to manage physical changes) and to explore its usability. Methods: At the last treatment appointment, early-stage breast, prostate, colorectal, and thoracic cancer patients (N = 340) recruited from community clinical oncology practices and an academic medical center completed a baseline assessment and were randomized to receive either Facing Forward (n = 175) or an attention control booklet about the NCI's Cancer Information Service (n = 165). Patients completed follow-up assessments at 8 weeks and 6 months post-baseline. Results: The reported uptake of recommended stress management behaviors was greater among intervention than control participants at both 8 weeks post-baseline (p = 0. 016) and 6 months post-baseline (p = 0. 017). At 8 weeks post-baseline, the intervention control group difference was greater among African-American than Caucasian participants (p < 0.03) and significant only among the former (p < 0.003); attendance at a cancer support group was also greater among the intervention than control group participants (p < 0.02). There were no significant intervention control group differences in the reported uptake of recommended behaviors in three other categories (p > 0.025). Intervention participants rated Facing Forward as understandable and helpful and indicated a high level of intention to try the behaviors recommended. Conclusions: Facing Forward can enhance early-stage survivors' reported ability to manage stress and increase support group use during the reentry period. Implications for Cancer Survivors: Facing Forward can help survivors meet the challenges of the reentry period. © 2012 Springer Science+Business Media New York.